Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019

慢性腎臓病(CKD)治療薬の世界市場2015-2019

◆タイトル:Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019
◆商品コード:IRTNTR5417
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年3月11日
◆ページ数:103
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、慢性腎臓病(CKD)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、慢性腎臓病(CKD)治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・慢性腎臓病(CKD)治療薬の世界市場:市場規模及び予測
・慢性腎臓病(CKD)治療薬の世界市場:地域別分析
・市場シェア
・購買基準
・市場成長要因
・市場の課題
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.

TechNavio’s analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.

[Covered in this Report]
The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.

TechNavio’s report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• EMEA
• APAC

[Key Vendors]
• Actavis PLC
• Amgen Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Sanofi

[Other Prominent Vendors]
• Abbott Laboratories
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Cara Therapeutics
• FibroGen
• Keryx Biopharmaceuticals
• Reata Pharmaceuticals
• OPKO Health
• Pharmacosmos
• Raptor Pharmaceuticals
• Regulus Therapeutics
• Rockwell Medical
• Shield Therapeutics
• Takeda Pharmaceuticals
• Vifor Pharma Ltd
• Xenetic Biosciences
• ZS Pharma

[Market Driver]
• Increase in Associated Disorders with CKD
• For a full, detailed list, view our report

[Market Challenge]
• Genericization of Major Brands
• For a full, detailed list, view our report

[Market Trend]
• Approval of New Pipeline Drugs
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Aranesp
04.1.2 Epogen/Procrit
04.1.3 Mircera
04.1.4 Renvela
04.1.5 Avapro
04.1.6 Bystolic

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Etiology
07.2 Epidemiology
07.2.1 Mortality
07.2.2 Prevalence of CKD

08.Pipeline Analysis
08.1 Emerging Treatment Options

09.Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis

10.Segmentation of Global CKD Market by Route of Administration
10.1 Oral
10.2 SC
10.3 IV

11.Segmentation of Global CKD Market by Mechanism of Action
11.1 ARBs
11.2 ACEIs
11.3 ESAs
11.4 PH Binders
11.5 Vasodilators

12.Geographical Segmentation
12.1 CKD Drugs Market in Americas
12.1.1 Market Size and Forecast
12.2 CKD Drugs Market in EMEA Region
12.2.1 Market Size and Forecast
12.3 CKD Drugs Market in APAC Region
12.3.1 Market Size and Forecast

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of Top Drugs Used for CKD Treatment
20.2.2 Amgen
20.2.3 Actavis
20.2.4 Johnson & Johnson
20.2.5 F. Hoffmann-La Roche
20.2.6 Sanofi
20.3 Other Prominent Vendors

21.Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Actavis
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 Johnson & Johnson
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Geographical Segmentation by Revenue 2013
21.3.6 Business Strategy
21.3.7 Recent Developments
21.3.8 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Sanofi SA
21.5.1 Key Facts
21.5.2 Business Description
21.5.3 Business Segmentation
21.5.4 Revenue by Business Segmentation
21.5.5 Revenue Comparison 2012 and 2013
21.5.6 Sales by Geography
21.5.7 Business Strategy
21.5.8 Key Developments
21.5.9. SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Segmentation of Global CKD Drugs Market
Exhibit 2: Market Research Methodology
Exhibit 3: Stages of CKD
Exhibit 4: Causes of CKD
Exhibit 5: Prevalence of CKD among NHANES (US) Participants by CKD Stage 1988-2012
Exhibit 6: Global CKD Drugs Market 2014-2019 (US$ billion)
Exhibit 7: Drivers and Challenges in Global CKD Drugs Market
Exhibit 8: Segmentation of Global CKD Drugs Market by Route of Administration
Exhibit 9: Segmentation of Global CKD Drugs Market by Mechanism of Action
Exhibit 10: Segmentation of Global CKD Drugs Market by Geography 2014
Exhibit 11: Segmentation of Global CKD Drugs Market by Geography 2019
Exhibit 12: Segmentation of Global CKD Drugs Market by Geography 2014-2019
Exhibit 13: CKD Drugs Market in Americas 2014-2019 (US$ billion)
Exhibit 14: CKD Drugs Market in EMEA Region 2014-2019 (US$ billion)
Exhibit 15: CKD Drugs Market in APAC Region 2014-2019 (US$ billion)
Exhibit 16: Comparison of Percentage of Population Age 65 and Older 2012 and 2050
Exhibit 17: Revenue Comparison of Top Drugs Used for Treatment of CKD 2013 (US$ million)
Exhibit 18: Epogen: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 19: Aranesp: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
Exhibit 20: Bystolic: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 21: Procrit: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 22: Mircera: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 23: Renvela: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 24: Avapro: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
Exhibit 25: Amgen: Business Segmentation by Revenue 2013
Exhibit 26: Amgen: Product Portfolio by Revenue 2013
Exhibit 27: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 28: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 29: Global CKD Drugs Market Market Business Segmentation 2013
Exhibit 30: Global CKD Drugs Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 31: Actavis : Sales by Geography (in US$ million)
Exhibit 32: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 33: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 34: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 35: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 36: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 37: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 39: Sanofi SA: Business Segmentation
Exhibit 40: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 41: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 42: Sanofi SA: Sales Revenue by Geographical Segmentation 2013



【掲載企業】

Actavis, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Sanofi, Abbott Laboratories, Akebia Therapeutic, AMAG Pharmaceuticals, Cara Therapeutics, FibroGen, KeryxBiopharmaceuticals, OPKO Health, Pharmacosmos, Raptor Pharmaceuticals, Reata Pharmaceuticals, Regulus Therapeutics, Rockwell Medical, Shield Therapeutics,Takeda Pharmaceuticals, Vifor Pharma Ltd, Xenetic Biosciences, ZS Pharma

【資料のキーワード】

慢性腎臓病(CKD)治療薬、ARB、ACEI、ESA、PHバインダー、血管拡張剤、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[慢性腎臓病(CKD)治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆